Publications

Influenza
Rotavirus
IMPACT
Meningococcal
Hepatitis B
HPV
Immunology
Immunization Programs & Safety
Varicella
Adult Immunization

Influenza

• Lei Y, Pereira JA, Quach S, Bettinger JA et al, Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Program Delivery and Evaluation Group. Examining perceptions about mandatory influenza vaccination of healthcare workers through online comments on news stories.  PLoS ONE 2015;10(6):e129993.
• Yam KK, Scheifele D et al. High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (ASO3) Influenza vaccine.  J Clin Immunol. 14 May 2014: DOI 10.1007/s10875-014-0054-2.

• Pereira JA, Quach S, Hamid JS, Heidebrecht CL, Quan SD, Nassif J, Diniz AJ, Van Exan R, Malawski J, Gentry A, Finkelstein M, Guay M, Buckeridge DL, Bettinger JA, Kalailieff D, Kwong JC; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Vaccine Coverage Theme Group. (2012) Exploring the feasibility of integrating barcode scanning technology into vaccine inventory recording in seasonal influenza vaccination clinics. Vaccine. 2012 Jan 17;30(4):794-802. doi: 10.1016/j.vaccine.2011.11.043. Epub 2011 Nov 23.

• De Serres G, Gariépy MC, Coleman B, Rouleau I, McNeil S, Benoît M, McGeer A, Ambrose A, Needham J, Bergeron C, Grenier C, Sleigh K, Kallos A, Ouakki M, Ouhoummane N, Stiver G, Valiquette L, McCarthy A, Bettinger J; PHAC-CIHR influenza Research Network (PCIRN). (2012) Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine. PLoS One. 2012;7(7):e38563. doi: 10.1371/journal.pone.0038563. Epub 2012 Jul 3.

• Scheifele DW, Ward BJ, Dionne M, Vanderkooi OG, Loeb M, Coleman BL, Li Y; PHAC/CIHR Influenza Research Network (PCIRN). (2012) Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial. Vaccine. 2012 Jul 6;30(32):4728-32. doi: 10.1016/j.vaccine.2012.05.029. Epub 2012 May 28.

• Tran D, Vaudry W, Moore DL, Bettinger JA, Halperin SA, Scheifele DW, Aziz S; IMPACT investigators.  (2012) Comparison of children hospitalized with seasonal versus pandemic influenza A, 2004-2009. Pediatrics. 2012 Sep;130(3):397-406. Epub 2012 Aug 29.

• Quach S, Pereira JA, Hamid JS, Crowe L, Heidebrecht CL, Kwong JC, Guay M, Crowcroft NS, McGeer A, Chambers LW, Quan SD, Bettinger JA; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network PCIRN Vaccine Coverage Theme Group; Canadian Healthcare Influenza Immunization Network. (2013) Measuring influenza immunization coverage among health care workers in acute care hospitals and continuing care organizations in Canada. Am J Infect Control. 2013 Apr;41(4):340-4. doi: 10.1016/j.ajic.2012.04.333. Epub 2012 Aug 15.

Rotavirus

• Le Saux N, Bettinger J, Déry P, Embree J, Vaudry W, Halperin SA, McDermid A, Booth TF, Coyle D. (2012) The hidden costs and characteristics of childhood rotavirus emergency visits in Canada. Pediatr Infect Dis J. 2012 Feb;31(2):159-63. doi: 10.1097/INF.0b013e3182375011.

• Coyle D,  Coyle K , Bettinger JA,  Halperin SA, Vaudry W, Scheifele DW, Le Saux N. (2012) Cost effectiveness of infant vaccination for rotavirus in Canada. Can J Infect Dis Med Microbiol. 2012 Summer;23(2):71-77

•  McDermid A, Le Saux N, Grudeski E, Bettinger JA, Manguiat K, Halperin SA, Macdonald L, Déry P, Embree J, Vaudry W, Booth TF; Members of the Canadian Immunization Monitoring Program, Active. (2013) Molecular characterization of rotavirus isolates from select Canadian pediatric hospitals. BMC Infect Dis. 2012 Nov 15;12:306. doi: 10.1186/1471-2334-12-306

IMPACT

• Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R, for the members of the Canadian Immunization Monitoring Program, Active (IMPACT). Diversity of Canadian meningococcal serogroup B isolates and estimated coverage of an investigational meningococcal serogroup B vaccine (4CMenB).  Vaccine (2014); 32(1):124-130. Paper
• Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, Bettinger JA, for the investigators of the Canadian Immunization Monitoring Program, ACTive (IMPACT). The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012.  Clin Infect Dis 2014; 59(9):1208-15.
• Sadarangani M, Schefiele DW, Halperhin SA, Vaudry W, Le Saux N, Tsang R, Bettinger JA, for the investigators of the Canadian Immunization Monitoring Program, ACTive (IMPACT). Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort paper. Clin Infect Dis 2015.
• Burton C, Vaudry W, Moore D, Bettinger JA, Tran D, Halperin SA, Scheifele DW for the IMPACT Investigators. Burden of seasonal influenza in children with neurodevelopmental conditions. Pediatr Infect Dis J 2014; 33:710-714

• McDermid A, Le Saux N, Grudeski E, Bettinger JA, Manguiat K, Halperin SA, Macdonald L, Déry P, Embree J, Vaudry W, Booth TF; Members of the Canadian Immunization Monitoring Program, Active. (2013) Molecular characterization of rotavirus isolates from select Canadian pediatric hospitals. BMC Infect Dis. 2012 Nov 15;12:306. doi: 10.1186/1471-2334-12-306

• Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Members of Canadian Immunization Monitoring Program, Active (IMPACT). (2013) The disease burden of invasive meningococcal serogroup B disease in Canada.  Pediatr Infect Dis J. 2013 Jan;32(1):e20-5. doi: 10.1097/INF.0b013e3182706b89.

• Bettinger JA, Deeks SL, Halperin SA, Tsang R, Scheifele DW. (2013) Controlling serogroup B invasive meningococcal disease: the Canadian perspective. Expert Rev Vaccines. 2013 May;12(5):505-17. doi: 10.1586/erv.13.30.

• Le Saux N, Bettinger J, Déry P, Embree J, Vaudry W, Halperin SA, McDermid A, Booth TF, Coyle D. (2012) The hidden costs and characteristics of childhood rotavirus emergency visits in Canada. Pediatr Infect Dis J. 2012 Feb;31(2):159-63. doi: 10.1097/INF.0b013e3182375011.

• Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Sáfadi MA. (2012) The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012 May 30;30 Suppl 2:B26-36. doi: 10.1016/j.vaccine.2011.12.032. Epub 2011 Dec 15.

• Coyle D,  Coyle K , Bettinger JA,  Halperin SA, Vaudry W, Scheifele DW, Le Saux N. (2012) Cost effectiveness of infant vaccination for rotavirus in Canada. Can J Infect Dis Med Microbiol. 2012 Summer;23(2):71-77

• Tan B, Bettinger J, McConnell A, Scheifele D, Halperin S, Vaudry W, Law B; Members of the Canadian Immunization Monitoring Program, Active (IMPACT).  (2012) The effect of funded varicella immunization programs on varicella-related hospitalizations in IMPACT centers, Canada, 2000-2008.  Pediatr Infect Dis J. 2012 Sep;31(9):956-63.

• Tran D, Vaudry W, Moore DL, Bettinger JA, Halperin SA, Scheifele DW, Aziz S; IMPACT investigators.  (2012) Comparison of children hospitalized with seasonal versus pandemic influenza A, 2004-2009. Pediatrics. 2012 Sep;130(3):397-406. Epub 2012 Aug 29.

Meningococcal

• Sadarangani M, Schefiele DW, Halperhin SA, Vaudry W, Le Saux N, Tsang R, Bettinger JA, for the investigators of the Canadian Immunization Monitoring Program, ACTive (IMPACT) (2015) Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort paper. Clin Infect Dis 2015
• Sáfadi MA, Bettinger JA, Maturana GM, Enwere G, Borrow R; On behalf of the Global Meningococcal Initiative (2014) Evolving meningococcal immunization strategies. Expert Rev Vaccines 2014; 1-13. (Epub ahead of print)
• Khatami A, Snape MD, Davis E, Layton H, John T, Yu LM, Dull PM, Gill CJ, Odrjlin T, Dobson S, Halperin SA, Langley JM, McNeil SA, Pollard AJ. (2012) Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine. 2012 Apr 16;30(18):2831-8. doi: 10.1016/j.vaccine.2012.02.046. Epub 2012 Mar 3.

• Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Sáfadi MA. (2012) The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012 May 30;30 Suppl 2:B26-36. doi: 10.1016/j.vaccine.2011.12.032. Epub 2011 Dec 15.

• Holst J, Nøkleby H, Bettinger JA. (2012) Considerations for controlling invasive meningococcal disease in high income countries. Vaccine. 2012 May 30;30 Suppl 2:B57-62. doi: 10.1016/j.vaccine.2011.12.093.

• Bettinger JA, Scheifele DW, Halperin SA, Kellner JD, Vanderkooi OG, Schryvers A, De Serres G, Alcantara J. (2012) Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis. Vaccine. 2012 Jun 8;30(27):4023-7. doi: 10.1016/j.vaccine.2012.04.034. Epub 2012 Apr 23.

• Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Members of Canadian Immunization Monitoring Program, Active (IMPACT). (2013) The disease burden of invasive meningococcal serogroup B disease in Canada.  Pediatr Infect Dis J. 2013 Jan;32(1):e20-5. doi: 10.1097/INF.0b013e3182706b89.

• Bettinger JA, Deeks SL, Halperin SA, Tsang R, Scheifele DW. (2013) Controlling serogroup B invasive meningococcal disease: the Canadian perspective. Expert Rev Vaccines. 2013 May;12(5):505-17. doi: 10.1586/erv.13.30.

Hepatitis B

• Pinto M, Scheifele DW. Discussing the need for an adolescent hepatitis B vaccine booster in infant vaccines. Paediatr Child Health. 19(8):404. (2014)

HPV

• Ogilvie GS, Naus M, Money DM, Dobson SR, Miller D, Krajden M, van Niekerk DJ, Coldman AJ. Reduction in cervical dysplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.  Int J Cancer. (2015) Mar 6. doi: 10.1002/ijc.29508. [Epub ahead of print]
• Krajden M.  Cook D.  Yu A.  Chow R.  Su Q.  Mei W.  McNeil S.  Money D.  Dionne M.  Palefsky J.  Karunakaran K.  Kollmann T.  Ogilvie G.  Petric M. Dobson S. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine.  32(5):624-30, (2014) Jan 23.

• Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G, Krajden M, Fortuno ES 3rd, Kollmann TR. (2012) Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine. 2012 May 21;30(24):3572-9. doi: 10.1016/j.vaccine.2012.03.051. Epub 2012 Mar 31.

• Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E. (2013) Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013 May 1;309(17):1793-802. doi: 10.1001/jama.2013.1625.

Immunology

• Slogrove AL, Goetghebuer T, Cotton MF, Singer J, Bettinger JA. Pattern of infectious morbidity in HIV exposed uninfected infants and children. Front. Immunol., 2016 May.
• Kollmann, TR.  BCG modulates neonatal innate immune cytokine production. J Infect Dis (2014). Advanced access published October 27.
• Slogrove A, Reikie B, Naidoo S, De Beer C, Ho K, Cotton M, Bettinger J, Speert D, Esser M, Kollmann T. (2012) HIV-exposed uninfected infants are at increased risk for severe infections in the first year of life. J Trop Pediatr. 2012 Dec;58(6):505-8. doi: 10.1093/tropej/fms019. Epub 2012 May 3.

• Gantt S, Yao L, Kollmann TR et el.  Implications of age-dependent immune responses to Enterovirus 71 infection for disease pathogenesis and vaccine design.  JPID 2013;2:162-170.

Immunization Programs & Safety

• Scheifele DW, Ferguson M, Predy G, Dawar M, Assudani D, Kuriyakose S, Van Der Meeren O, Htay-Htay H. Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants. Vaccine 2015; ahead of print.
• Thollot F, Scheifele D, Pankow-Culot H et al. A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4, and 12 months of age. Pediatr Infect Dis J  2014, 33(12): 1246-54

• Scheifele DW, Ward BJ, Halperin SA et al. Approved but non-funded vaccines: accessing individual protection. Vaccine 2014

• Scheifele DW, Halperin SA, Bettinger JA. Childhood immunization rates in Canada are too low: UNICEF. Paediatrics & Child Health 2014;19:237-8

• Omura J, Buxton J, Scheifele D, Dawar M et al. Immunization delivery in British Columbia.  Canadian Family Physician 2014;60:e187-e193

• Dubé E, Gilca V, Sauvageau C, Bettinger JA, Boucher FD, McNeil S, Gemmill I, Lavoie F, Ouakki M, Boulianne N. Clinicians’ opinions on new vaccination programs implementation. Vaccine. 2012 Jun 29;30(31):4632-7. doi: 10.1016/j.vaccine.2012.04.100. Epub 2012 May 11

• Al-Dabbagh M, Lapphra K, Scheifele DW, Halperin SA, Langley JM, Cho P, Kollmann TR, De Serres G, Fortuno ES, Bettinger JA.  Elevated inflammatory mediators in adults with oculorespiratory syndrome following influenza immunization: a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network Study.  Clin Vaccine Immunol 2013;20:1108-1114.

• LaFleche J, Bettinger JA, Scheifele DW, Vaudry W, Halperin SA, Law BJ. Applicability of the Brighton Collaboration case definition for seizure after immunization in active and passive surveillance in Canada.  Top KA, Constantinescu CM, Vaccine 2013; xx

• Dubé E, Laberge C, Guay M, Bramadat P, Roy R and Bettinger J. Vaccine hesitancy: An overview. Human Vaccines & Immunotherapeutics 2013; 9(8):1-11.

• McNeil MM, et al. The vaccine safety datalink: successes and challenges monitoring vaccine safety. Vaccine 2014; 32: 5390-5398

Varicella (chicken pox)

• Tan B, Bettinger J, McConnell A, Scheifele D, Halperin S, Vaudry W, Law B; Members of the Canadian Immunization Monitoring Program, Active (IMPACT).  (2012) The effect of funded varicella immunization programs on varicella-related hospitalizations in IMPACT centers, Canada, 2000-2008.  <title=”The Pediatric infectious disease journal.” href=”http://www.ncbi.nlm.nih.gov/pubmed/22647896″>Pediatr Infect Dis J. 2012 Sep;31(9):956-63.

Adult Immunization

• Halperin SA, Scheifele D, De Serres G, Noya F, Meekison W, Zickler P, Larrivée L, Langley JM, McNeil SA, Dobson S, Jordanov E, Thakur M, Decker MD, Johnson DR. (2012) Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine. 2012 Jan 20;30(5):974-82. doi: 10.1016/j.vaccine.2011.11.035. Epub 2011 Nov 21.

• Schneeberg A, Bettinger JA, McNeil S et al.  Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization: a Public Health of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation.  BMC Public Health 2014